



Telix Pharmaceuticals Limited
ACN 616 620 369
Suite 401, 55 Flemington Road
North Melbourne
Victoria, 3051
Australia

Job Description: Senior Radiochemist: Director of Targeted Alpha Therapy Research

Type: Full Time

Location: Australia, Europe or United States

Date: Immediate

About Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited ("Telix", the "Company") is an Australian public Company (ASX:TLX) headquartered in Melbourne with operations in Europe, the US and Japan. Our mission is to be a leading, global biopharmaceutical Company in the field of "theranostic" radiopharmaceuticals and the Company is currently developing a mid-late stage pipeline of products in oncology and rare diseases.

About the Role

Telix is expanding and searching for a research-oriented radiochemist with experience of alpha-emitting radioisotopes acting in the role of Director or VP of Targeted Alpha Research to contribute to the achievement of the Group's strategic goals by leading research projects in the field of Targeted Alpha Therapy (TAT). This role reports directly to the Chief Scientist and works closely with other internal R&D members, preclinical manager and clinical and project teams across multiple disciplines. As a growth area of research for Telix, the initial incumbent will have the opportunity to determine the strategic direction of the company's targeted alpha strategy by developing, planning and initiating a research theme around alpha-emitting radioisotopes & related technologies.

Other key accountabilities include:

- Leading the TAT research strategy in the company by developing and implementing a long-term research strategy will create platform capabilities & add value to Telix's proprietary products and pipeline
- Prioritising and driving research projects with a commercial mindset to evaluate, optimise and ultimately deliver meaningful research outcomes
- Leading collaborations and partnerships with strategic partners relating to the production, radiolabelling processes, chelator chemistry and in vivo evaluation of relevant alpha-emitting radioisotopes
- Ensuring the delivery of ongoing and future projects by building capability through various channels
- Supporting colleagues by providing technical input on the design and interpretation of clinical studies with TAT agents.
- Maintaining an awareness of the current literature, developments in the field and encouraging strategic partnerships with companies or academic groups to identify best industry practice
- Managing program timelines, resources & budgets.

About You

You can work remotely from one of our key regions or in a hybrid arrangement however to be considered, you must hold a PhD in a quantitative discipline (e.g., chemistry, radiochemistry) or equivalent practical experience in a production environment. You have relevant applied research experience working in radiopharmaceuticals, molecular-targeted radiation and, ideally with alpha-emitting radioisotopes and experience in a commercial environment. You possess a solid understanding of the drug development process including preclinical studies, cGMP principles, clinical studies and regulatory processes and have demonstrated knowledge of the TAT research

field including relevant topics of radiochemistry, isotopes (and their supply chain), chelators, targeting agents and radiobiology. Ideally you can manage complex technical research programs and successful 3rd party academic or commercial collaborations and have the commerciality to confidently guide corporate strategy in this area.

Why work at Telix?

We are a dynamic, fast-growing biopharmaceutical company where employees have a shared purpose: to help people with cancer and rare diseases live longer, better quality lives. This is an exciting time for Telix and we are looking for like-minded, passionate professionals to join us on the journey.

No agency submissions will be considered for this role.